The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.
Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky. Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
6
10 mL Hydrogel
Brigham and Women's Hospital
Boston, Massachusetts, United States
Caritas St Elizabeth's Medical Center
Boston, Massachusetts, United States
SAEs - Safety
Time frame: 1 year post treatment
PFTs
Time frame: 12 weeks post treatment
Dyspnea
Time frame: 12 weeks post treatment
Exercise capacity
Time frame: 12 weeks post treatment
QOL
Time frame: 12 weeks post treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.